PA
REGN icon

Pinnacle Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Pinnacle Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-900
Closed -$338K – 712
2019
Q4 		$338K Buy
+900
New +$303K 0.01% 590

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pinnacle Associates's REGN Position: Q2 2026 in Review

Pinnacle Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q2 2026, selling an estimated $861K and leaving 81,247 shares worth $50.7M. The position accounts for 0.55% of the portfolio, ranked #38.

Pinnacle Associates first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $190M in Q3 2013. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Pinnacle Associates held 81,247 shares of Regeneron Pharmaceuticals worth $50.7M as of Q2 2026.
  • Pinnacle Associates sold 1,265 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $861K.
  • Regeneron Pharmaceuticals made up 0.55% of Pinnacle Associates's portfolio in Q2 2026, its #38 holding.
  • Pinnacle Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Pinnacle Associates's Regeneron Pharmaceuticals position peaked at $190M in Q3 2013.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.